Fig. 1

CloneSight assay workflow. Schematic representation of the clinical pathway for HR + breast cancer (BC) patients, including treatment and blood collection. Patientsunderwent neoadjuvant chemotherapy (if applicable) and received at least 5 years of endocrine therapy. Plasma samples were collected during and/or after endocrine therapy at 6‐month intervals during 2 years. Tumor tissue obtained at the time of initial BC diagnosis was evaluated for suitability. DNA was extracted from these samples, and whole exome sequencing was performed to identify somatic mutations unique to each patient. These mutations were subsequently used to develop personalized CloneSight assays for minimal residual disease (MRD) detection